Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antiangiogenic agents and their promising potential in combined therapy
Autore:
Burke, PA; DeNardo, SJ;
Indirizzi:
Univ Calif, Davis Med Ctr, Dept Internal Med, Div Hematol Oncol, Sacramento, CA 95816 USA Univ Calif Sacramento CA USA 95816 ematol Oncol, Sacramento, CA 95816 USA Univ Calif, Davis Med Ctr, Dept Internal Med, Sect Radiodiag & Therapy, Sacramento, CA 95816 USA Univ Calif Sacramento CA USA 95816 ag & Therapy, Sacramento, CA 95816 USA
Titolo Testata:
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
fascicolo: 1-2, volume: 39, anno: 2001,
pagine: 155 - 171
SICI:
1040-8428(200107/08)39:1-2<155:AAATPP>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENDOTHELIAL GROWTH-FACTOR; ANGIOGENESIS INHIBITOR TNP-470; LEWIS LUNG-CARCINOMA; INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS; CYTOTOXIC CANCER THERAPIES; TUMOR-GROWTH; MONOCLONAL-ANTIBODY; IN-VIVO; IONIZING-RADIATION; SOLID TUMORS;
Keywords:
angiogenesis; antiangiogenic therapy; radioimmunotherapy; cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
166
Recensione:
Indirizzi per estratti:
Indirizzo: DeNardo, SJ Univ Calif, Davis Med Ctr, Dept Internal Med, Div Hematol Oncol, 1508 Alhambra Blvd, Sacramento, CA 95816 USA Univ Calif 1508 Alhambra Blvd Sacramento CA USA 95816 5816 USA
Citazione:
P.A. Burke e S.J. DeNardo, "Antiangiogenic agents and their promising potential in combined therapy", CR R ONC H, 39(1-2), 2001, pp. 155-171

Abstract

One of the most promising strategies for treating cancer is the addition of antiangiogenic therapy to therapeutic regimens. Angiogenesis, or the growth of new blood vessels from preexisting vessels, is essential both for thegrowth of a primary tumor and for successful metastasis. As a result of intense research in this field, a number of antiangiogenic agents have been identified and have demonstrated varying degrees of success in inhibiting the growth of solid tumors and metastases in preclinical and clinical studies. The real potential of antiangiogenic agents for cancer therapy resides instrategic combinations with each other, with chemotherapy, with radiation,and with tumor-targeting agents, such as radioimmunotherapy. Along with this new opportunity to develop synergistic therapy comes the challenging complexities of the physiologic systems regulating angiogenesis. These multifaceted systems could intimidate investigators seeking to take advantage of the potential synergy in combined cancer therapy. To aid in these efforts, this overview of key antiangiogenic agent mechanisms, combination strategiesand initial studies of the potential synergy with chemotherapy, radiation and radioimmunotherapy is presented. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 00:37:42